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Progression of breast cancer involves cross-talk be-
tween epithelial and stromal cells. This cross-talk is
mediated by growth factors and cytokines secreted by
both cancer and stromal cells. We previously reported
expression of interleukin (IL)-1 in a subset of breast
cancers and demonstrated that IL-1 is an autocrine
and paracrine inducer of prometastatic genes in in
vitro systems. To understand the role of IL-1 in
breast cancer progression in vivo , we studied the
growth of MCF-7 breast cancer cells overexpressing a
secreted form of IL-1 (MCF-7IL-1) in nude mice.
MCF-7IL-1 cells formed rapidly growing estrogen-
dependent tumors compared to parental cells. Inter-
estingly, IL-1 expression alone was not sufficient for
metastasis in vivo although in vitro studies showed
induction of several prometastatic genes and matrix
metalloproteinase activity in response to cross-talk
between IL-1-expressing cancer cells and fibro-
blasts. Animals implanted with MCF-7IL-1 cells were
cachetic, which correlated with increased leptin se-
rum levels but not other known cachexia-inducing
cytokines such as IL-6, tumor necrosis factor, or in-
terferon gamma. Serum triglycerides, but not blood
glucose were lower in animals with MCF-7IL-1 cell-
derived tumors compared to animals with control
cell-derived tumors. Cachexia was associated with at-
rophy of epidermal and adnexal structures of skin; a
similar phenotype is reported in triglyceride-defi-
cient mice and in ob/ob mice injected with leptin.
Mouse leptin-specific transcripts could be detected
only in MCF-7IL-1 cell-derived tumors, which sug-
gests that IL-1 increases leptin expression in stromal
cells recruited into the tumor microenvironment. De-
spite increased serum leptin levels, animals with
MCF-7IL-1 cell-derived tumors were not anorexic
suggesting only peripheral action of tumor-derived
leptin, which principally targets lipid metabolism.
Taken together, these results suggest that cancer cell-
derived cytokines, such as IL-1 , induce cachexia by
affecting leptin-dependent metabolic pathways.
(Am J Pathol 2003, 163:2531–2541)
Progression of breast cancer from a benign to a malig-
nant stage is accompanied by overexpression of several
growth factors, cytokines, and chemokines by cancer
cells.1–4 These growth factor/cytokine expression pat-
terns can predict clinical outcome because they can
influence disease progression by enhancing metastasis
or inducing cachexia without any distant metastasis. In
fact, 30% of cancer mortality is because of cachexia
rather than tumor burden or metastasis.5
The major circulating cytokines implicated in breast
cancer progression include tumor necrosis factor
(TNF)-, interleukin (IL)-6, and IL-8.4,6 In various experi-
mental models, all three of these cytokines can promote
cancer progression by enhancing both metastasis and
cachexia.7–9 Others and we reported the expression of
IL-1 in primary breast cancer and breast cancer cell
lines with highly metastatic phenotype.10,11 Invasive
breast cancers and ductal carcinoma in situ express
higher levels of IL-1 compared to benign tumors.11 In
breast cancer cell lines, increased IL-1 expression cor-
related with constitutive DNA binding of extracellular sig-
nal-activated transcription factor nuclear factor (NF)-B,
and expression of prometastatic (IL-6 and IL-8) and anti-
apoptotic genes (TRAF-1 and cIAP-2).10,12,13 Further-
more, IL-1 from breast cancer cells induced NF-B in
stromal cells, which was accompanied by increased ex-
pression of urokinase plasminogen activator (uPA), IL-6,
and IL-8 in stromal fibroblasts.10,14 Results of these in
vitro studies suggest that IL-1 is involved in invasion and
metastatic growth of breast cancer.
IL-1 is usually expressed as a preprotein, which is
secreted only after cleavage by the calpain family of
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proteases.15 Calpains cleave pre-IL-1 and release the
N-terminal propiece-IL-1 and the C-terminal secreted
IL-1.16 Unlike IL-1, which is biologically active only as
a secreted mature molecule, membrane-associated IL-
1, propiece-IL-1, and mature secreted IL-1 show dis-
tinct biological activities.15 The propiece-IL-1 has trans-
forming activity whereas secreted IL-1 has paracrine
and autocrine activities similar to IL-1.15,17 Membrane-
associated IL-1 potentiates anti-tumor immunity.18
Transformed but not normal epithelial cells secrete IL-1,
possibly because of overexpression of calpain family
proteases by cancer cells.15,19 Because IL-1 is overex-
pressed in a variety of cancers including breast, squa-
mous cell carcinoma, and melanoma,11,20,21 we initiated
this study to specifically address the role of secreted
IL-1 in breast cancer progression. The aims of this study
were to investigate the effects of a cancer cell-derived
secreted form of IL-1 on general metabolic status and to
test whether IL-1 expression alone is sufficient to con-
vert MCF-7 breast cancer cells from nonmetastatic to
metastatic phenotype. MCF-7 cells do not express IL-1
and form estrogen-dependent, nonmetastatic tumors in
nude mice.10,22 We show that IL-1 expression alone is
not sufficient to induce metastasis of these cells despite
increasing prometastatic gene expression in stromal
cells in in vitro studies. However, IL-1 alone was able to
induce profound cachexia. Cachexia was accompanied
with atrophy of epidermal and adnexal structures of skin.
Interestingly, cachexia in animals with IL-1-overex-
pressing cell-derived tumors correlated with elevated se-
rum leptin and reduced triglyceride levels but not with
any other known cachexia-inducing cytokines.
Materials and Methods
Breast Cancer Cell Lines and Generation of
Breast Cancer Cells Overexpressing IL-1
MCF-7 and human lung fibroblasts (HLF-1) were pur-
chased from American Type Culture Collection, Rock-
ville, MD, and maintained in minimal essential medium
plus 10% fetal calf serum and antibiotics. To generate
MCF-7 cells overexpressing the human mature secreted
form of IL-1, we amplified sequences corresponding to
amino acids 122 to 271 of full-length IL-123 by polymer-
ase chain reaction (PCR) and cloned it into BamHI-XbaI
sites of the pcDNA3 or the modified pCMV4 vector
(pCMV4 vector has an alfalfa mosaic virus translation
enhancer, which increases translation efficiency). MCF-7
cells were transfected with these vectors and grown in
the presence of G418 (600 g/ml) to select transfected
cells. G418-resistant colonies were isolated and grown
individually.
Implantation of Cells into Mammary Fat Pads of
Nude Mice, Tumor, and Animal Weight
Measurements
All animal studies were performed with the approval from
Institutional Animal Care and Use Committee and as per
the National Institutes of Health guidelines. MCF-7 breast
cancer cells with or without HLF-1 were injected into the
mammary fat pads of 6- to 8-week-old nu/nu mice (Harlan
Sprague Dawley, Indianapolis, IN) as described previ-
ously.24 Eight to ten animals per group were used in
every experiment described in the text and experiments
were repeated three times. Estrogen pellets (17 estra-
diol, 0.72 mg/pellet, 60 day release; Innovative Research
of America, Sarasota, FL) were implanted a day before
tumor cell injection. Tumor growth was measured once a
week using a caliper (in mm) and tumor weight (mg) was
calculated using the formula tumor weight (mg)  (a2 
b)/2 where a is the width in mm and b is the length in
mm.25,26 Actual tumor weight was also measured at the
time of sacrifice to further confirm the results obtained
with the above formula. Animal weight was measured
once weekly and final body weight was calculated after
subtracting tumor weight.
Measurement of Blood Glucose, Serum
Cytokines, Triglycerides, Leptin, and Calcium
Blood glucose was measured using the Accu-Check ad-
vantage blood glucose monitor (Roche, Indianapolis, IN).
Serum was collected at the time of sacrifice. Serum cy-
tokines were measured using LINCOplex multiplex immu-
noassay system (Linco Research, Inc., Missouri, MO).
This assay system is highly sensitive and measures cy-
tokines as low as 3.2 pg/ml of serum (www.lincoresearch.
com). Leptin was also measured similarly. Serum calcium
was measured as described previously.27 IL-1 was
measured using an enzyme-linked immunosorbent assay
from R&D Systems as per the manufacturer’s recommen-
dation (R&D Systems, Minneapolis, MN). For enzyme-
linked immunosorbent assay, 1  106 cells were plated
for 2 days in 60-mm plates. After washing in PBS, cells
were incubated with 5 ml of serum-free media for 24
hours and media was analyzed for IL-1. The sensitivity
of the assay was 3.9 pg/ml.
Electrophoretic Mobility Shift Assays, Western
Blotting, Northern Blotting, and Gelatin
Zymography
Electrophoretic mobility shift assay with whole cell ex-
tracts was performed as described previously.28 For
Western blotting, finely minced thigh muscle was resus-
pended in radioimmunoassay buffer (RIPA, 50 mmol/L
Tris, pH 7.5, 0.25% sodium deoxycholate, 1% Nonidet
P-40, 150 mmol/L NaCl, 1 mmol/L ethylenediaminetet-
raacetic acid, 100 mol/L sodium orthovanadate, 1
mmol/L sodium fluoride, 1 mmol/L -glycerophosphate,
0.5 mmol/L phenylmethyl sulfonyl fluoride, 2 g/ml apro-
tinin, leupeptin, and pepstatin) and homogenized. Solu-
ble protein was used for Western blotting as described
previously.29 Northern blotting for IL-8 expression was
performed as described previously.28 For gelatin zymog-
raphy, conditioned media (CM) from 1  105 cells plated
overnight were used. For co-culturing, an equal number
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of cancer cells and HLF-1 were used. Zymography was
performed as described previously.30
Measurement of Proteasomal Activity
Thigh muscle collected at the time of sacrifice was ho-
mogenized in buffer Y (50 mmol/L Tris, pH 7.4, 250
mmol/L NaCl, 1% Triton X-100, 0.1% sodium dodecyl
sulfate, and 1 mmol/L ethylenediaminetetraacetic acid)31
and 20S proteasome activity was measured using an
assay kit from Chemicon International (Temecula, CA).
Analysis of Micrometastasis by PCR of
Lung DNA
Lung DNA was isolated and subjected to PCR analysis as
described by Endo and colleagues.32 One g of DNA
was subjected to 24 cycles of PCR using primers
5AGAGCCATCTATTGCTTACA3 and 5TATGACATGA-
ACTTAACCAT3. PCR products were identified by South-
ern blotting using the internal primer 5ACACAACTGT-
GTTCACTAGC3 as a probe.
Analysis of Tumors for the Expression of Leptin
and Lipid-Mobilizing Factor (LMF)
RNA from flash-frozen tumors was isolated by RNAzol
(Tel-Test Inc., Friendswood, TX). Five g of RNA was
reverse-transcribed using random primers and reverse
transcription (RT)-PCR kit (Stratagene, La Jolla, CA). Re-
verse-transcribed RNA (1/25 volume) was subjected to
PCR using specific primers. Primers used for amplifica-
tion of leptin were 5GGAGACCCCTGTGTCGGTTC3 and
5TCCAGGCTCTCTGGCTTCTG3; the internal primer used
was 5GATGACACCAAAACCCTCATC3. The primers
used for LMF were 5CTGTCCTGCTGTCTCTGCTG3 and
5TGGGCTGAGACTTCCTGTCT3; the internal primer used
was 5CTCCACTGGGCTGTCCAAGC3. GAPDH primers
that can amplify both human and mouse GAPDH were
5GAGGACCAGGTTGTCTCC3 and 5CCTTGGAGGCC-
ATGTAGG3. Southern blotting was performed as de-
scribed previously.10
Quantitative Measurements and Statistical
Analysis
Expression levels of MyoD and ubiquitinated proteins
were quantitated by densitometric scanning of Western
blots. Data were analyzed with GD-STAT or Graphpad
softwares. Analysis of variance was used to determine P
values between mean measurements. A P value of0.05
was deemed significant. Error bars on all graphs repre-
sent standard errors between measurements.
Results
Generation and Analysis of MCF-7 Breast
Cancer Cells Overexpressing IL-1
To study the effect of the secreted form of IL-1 on
growth of breast cancer cells in nude mice, we generated
a mammalian expression vector that codes for only the
mature secreted form (amino acids 122 to 271) of human
IL-1 (pcDNA3-IL-1).23 The expression of the secreted
form of IL-1 in MCF-7 cell colonies obtained after trans-
fection with either expression vector alone (pcDNA3-1, 2,
and 3) or IL-1 expression vector (MCF-7IL-1-4, 5, and
6) was measured by enzyme-linked immunosorbent as-
say. No measurable IL-1 could be detected in the CM of
pcDNA3 clones. In contrast, IL-15 and IL-16 CM con-
tained 100 and 24 pg/ml of IL-1, respectively. We also
measured NF-B DNA-binding activity in these cells be-
cause IL-1 expression should lead to autocrine activa-
tion of NF-B.33 Indeed, active NF-B protein levels, as
measured by DNA-binding activity, were elevated in
MCF-7IL-1 cells compared to pcDNA3 cells (Figure 1A).
NF-B activation in cancer cells correlated with in-
creased expression of proinvasive and prometastatic
genes IL-8 (data not shown) and CXCR4.34 However,
MCF-7IL-1 cells failed to express the NF-B regulated
prometastatic gene uPA, which could be because of
methylation of the uPA promoter in these cells.35
To further confirm that the secreted form of IL-1 is
biologically active, we treated HLF-1 with CM from
pcDNA3 or MCF-7IL-1 cells. CM from MCF-7IL-1 but
not pcDNA3 cells induced NF-B in HLF-1 (Figure 1B).
The NF-B:DNA complex obtained with HLF-1 cell ex-
tracts was a heterodimer of p65:p50 subunits of NF-B as
determined by antibody supershift assay (data not
shown). Induction of NF-B in HLF-1 by CM of MCF-
7IL-1 cells correlated with increased expression of the
NF-B responsive gene IL-8 (Figure 1C).
To determine the influence of IL-1 on growth of MCF-7
cells in nude mice, we implanted pcDNA3-1, IL-15, and
IL-16 cells (5  106) into mammary fat pads with or
without estrogen pellets. Tumors were obtained only in
animals with estrogen pellet implants, which were in gen-
eral larger in animals implanted with MCF-7IL-1 cells.
Because tumor intake was not uniform, we isolated tu-
mors from animals and grew them in culture in the pres-
ence of G418. All animal experiments described below
were performed with cells that have been passed through
nude mice once. This approach has been used by a
number of investigators to improve tumor intake in xeno-
graft models.3,36,37
Properties of Tumor-Derived pcDNA3 and IL-1
Cells
We first determined IL-1 expression in CM of tumor-
derived cell lines (named Td-pcDNA3 and Td-IL-1) by
enzyme-linked immunosorbent assay. IL-1 levels in CM
of Td-pcDNA3-1, Td-IL-11, Td-IL-12, and Td-IL-13
were 0, 218  4, 293  15, and 288  4 pg/ml, respec-
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tively. Reasons for the marked increase in IL-1 expres-
sion in tumor-derived IL-1 clones compared to the orig-
inal IL-1 clones in culture are not known. Although
parental IL-1-overexpressing cells were of clonal origin,
some cells may have lost IL-1 expression during pro-
longed culture because of lack of selection pressure. In
contrast, clonal selection of high IL-1-expressing cells in
animals may have contributed to elevated IL-1 expres-
sion in Td-IL-1 cells.
To determine the autocrine activity of IL-1, we mea-
sured NF-B DNA-binding activity in tumor-derived cell
lines and found that only Td-IL-1 cells contained con-
stitutive NF-B DNA-binding activity (Figure 2A, lanes 1
to 4). Furthermore, CM from only Td-IL-1 cells induced
NF-B DNA-binding activity in HLF-1 (Figure 2A, lanes 5
to 9). Neutralizing antibody against IL-1 but not leuke-
mia inhibitory factor blocked Td-IL-11 cell CM-mediated
NF-B activation in HLF-1 (Figure 2B). Induction of NF-B
by CM in HLF-1 correlated with increased expression of
IL-6, IL-8, and uPA in these cells (data not shown).
Td-pcDNA3-1 and Td-IL-13 cells (5  106) were im-
planted into the mammary fat pads with or without estro-
gen pellets. No tumors were obtained with either cell type
in the absence of estrogen. Thus, IL-1 cannot confer
hormone-independent growth properties to MCF-7 cells.
Figure 1. Generation of IL-1-overexpressing MCF-7 cells. A: NF-B DNA-
binding activity in MCF-7 cells transfected with pcDNA3 or IL-1 expression
vector. Individual G418-resistant colonies were examined for NF-B DNA-
binding activity by electrophoretic mobility shift assay. DNA binding of the
general transcription factor SP-1 is also shown. B: Induction of NF-B in
HLF-1 by the CM from pcDNA3 and IL-1-overexpressing clones. HLF-1 cells
were incubated with CM from indicated cell lines for 1 hour. NF-B and SP-1
DNA-binding activities were measured as described above. CM from 90%
confluent cells was collected after overnight incubation in serum-free media.
C: Induction of IL-8 in HLF-1 cells by CM from various cell types. HLF-1 was
incubated with CM for 4 hours and IL-8 expression was measured by North-
ern blotting of total RNA.
Figure 2. Properties of tumor-derived pcDNA3- and IL-1-overexpressing
clones. A: NF-B DNA-binding activity in pcDNA3- and IL-1-overexpressing
cells isolated from tumors and grown in culture (lanes 1 to 4). CM from the
same cells was tested for their ability to induce NF-B in HLF-1 cells (lanes
5 to 9). NF-B DNA binding was measured as in Figure 1A. B: Neutralizing
antibody against IL-1 blocks NF-B activation by Td-IL-11 CM. CM was
treated with the indicated neutralizing antibodies (3 g/ml) for 1 hour at
room temperature. Cells were treated with CM for 1 hour.
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Similarly, MCF-7 cells grown in the presence of exoge-
nous IL-1 failed to become hormone-independent (data
not shown). Both Td-pcDNA3-1 and Td-IL-13 cells
formed tumors in all animals with estrogen pellet im-
plants. After 7 weeks of implantation, tumor weight for the
Td-IL-13 and Td-pcDNA3-1 groups was 2042 383 mg
and 1044  297 mg, respectively. Thus, it seems that
IL-1 enhances the rate of tumor growth. Enhanced
growth of Td-IL-13-derived tumors is less likely because
of the increased sensitivity of these cells to estrogen, at
least at the genomic level because estrogen receptor
activity was similar in both Td-pcDNA3-1 and Td-IL-13
cells in in vitro assays (data not shown). Although Td-IL-
13-derived tumors grew faster, hematoxylin and eosin
(H&E) staining of lungs collected at the time of sacrifice
did not reveal any metastasis. Also, a similar level of
micrometastasis to lungs, as determined by PCR analysis
of lung DNA for the presence of human -globin se-
quences,32 was observed with both groups (data not
shown). Lack of metastasis of Td-IL-13-derived tumor is
not because of silencing of the transfected IL-1 gene in
the tumor because the serum of animals with Td-IL-13-
derived tumors but not Td-pcDNA3-1-derived tumors had
measurable IL-1 (15 to 69 pg/ml). Despite the lack of
metastasis, weight loss was observed in animals with
Td-IL-3-derived tumors (19.3  1.1 g) compared to
animals with Td-pcDNA3-1-derived tumors (22.3 
0.9 g). Note that animals in both groups were of similar
weight at the time of tumor cell implantation.
The Effect of Fibroblasts on Growth of Td-IL-
13 and Td-pcDNA3-1 Cells in Nude Mice
The failure of Td-IL-13-derived tumors to metastasize
could be because of the inability of these tumors cells to
recruit stromal cells, which provide matrix metalloprotein-
ases (MMPs) required for invasion and metastasis.38 To
test this possibility, we first determined MMP activity in
CM of parental pcDNA3 and IL-1 clones, Td-pcDNA3-1
and Td-IL-1 clones, and all cell types co-cultured with
HLF-1 using gelatin zymography.30 CM of pcDNA3,
HLF-1, or IL-1 clones showed very little MMP activity
(Figure 3A, lanes 1 to 8). MMP activity was modestly
higher in the CM of Td-pcDNA3-1 and HLF-1 co-culture
compared to pcDNA3 and HLF-1 co-culture (Figure 3A,
compare lanes 9 and 12). This increase in MMP activity in
CM of Td-pcDNA3-1 is independent of IL-1 because no
measurable IL-1 could be detected in CM of both
pcDNA3 and Td-pcDNA3-1 clones. CM of Td-IL-1 cells
co-cultured with HLF-1 displayed very strong MMP activ-
ity (Figure 3A, lanes 9 to 15). Based on the molecular
weight, it appears that secreted MMPs correspond to
MMP-9 and MMP-2, which are secreted by mammary
epithelial cells.39 Neutralizing antibody against IL-1 re-
duced MMP activity suggesting that IL-1 is required for
MMP activity (data not shown). At present it is not clear
whether MMPs are produced by Td-IL-1 cells or HLF-1
cells. However, a similar study published recently indi-
cates that fibroblasts but not MCF-7 cells produce
MMP-2 and MMP-9 under co-culture conditions.40 Co-
culturing is required for MMP production as incubating
HLF-1 cells with CM of Td-IL-1 cells or vice versa did not
result in significant increase in MMP activity (data not
shown). No uPA activity was detected under any culture
conditions when zymography was performed using hu-
man plasminogen as a substrate (data not shown).
We implanted both Td-pcDNA3-1 and Td-IL-13 cells
with or without HLF-1 cells because there was specific
increase in MMP activity in co-cultured cells. Unlike in
experiments described above, the number of tumor cells
was reduced to 2  106 per animals with or without 2 
105 HLF-1. Tumors derived from Td-IL-13 cells with or
without HLF-1 grew much faster than Td-pcDNA3-1 cells
and HLF-1 did not significantly alter the growth rate.
Therefore, Figure 3B shows combined tumor growth rate
of three independent experiments with or without HLF-1
(n  30). With lower numbers of implanted cells com-
pared to the previous experiment, differences in growth
rates between Td-pcDNA3-1 and Td-IL-13-derived tu-
mors are more apparent. The failure of HLF-1 to provide
additional growth advantage to Td-IL-13 cells in vivo
could be because of IL-1-dependent recruitment and/or
growth of mouse-derived stromal cells. Growth-stimulat-
ing ability of IL-1 was manifested within the tumor mi-
croenvironment but not in vitro because pcDNA3, IL-1,
Td-pcDNA3, and Td-IL-1 clones grew at a similar rate in
Figure 3. MMP activation and growth of Td-pcDNA3-1 and Td-IL-13 cells in
the presence of HLF-1 cells. A: Gelatin zymography using CM from either
cancer cells alone (lanes 1 to 7), HLF-1 (lane 8), or cancer cells in combi-
nation with HLF-1 cells. B: Rate of tumor growth. Cancer cells (2  106) with
or without HLF-1 cells (2  105) were injected into the mammary pads of
nude mice with estrogen pellet implants. Tumor growth was measured once
a week. C: Analysis of lung DNA for metastasis of cancer cells. DNA from
lungs was isolated and subjected to PCR with human -globin-specific
primers. As a control, PCR was also performed with primers that amplify
mouse requiem genomic DNA.77 Southern blotting using an internal primer
identified PCR products.
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culture (data not shown). H&E staining of tumors revealed
extensive central necrosis in Td-IL-13 cell-derived tu-
mors (data not shown). Despite enhanced growth of Td-
IL-13 cell-derived tumors, H&E staining of lungs did not
reveal metastasis of either cell type. Furthermore, PCR
analysis of lung DNA for human -globin gene revealed
similar levels of micrometastasis of Td-IL-13 and Td-
pcDNA3-1 tumor cells (Figure 3C). Thus, IL-1 expres-
sion alone is not sufficient to promote metastasis of
MCF-7 cells in an in vivo setting. However, we cannot rule
out IL-1-dependent metastasis of other breast cancer
cell types.
IL-1 Expression Leads to Severe Cachexia
Mice with Td-IL-13-derived tumors showed lordokypo-
sis (hunchback spine), which is an early aging-associ-
ated phenotype in mice.41 A significant progressive
weight loss was observed in animals injected with Td-IL-
13 cells compared to animals injected with Td-
pcDNA3-1 cells (P  0.0003) (Figure 4A). Animals in all
three groups (nontumor and Td-pcDNA3-1- and Td-IL-
13-derived tumor containing group) grew for first 3
weeks after implantation. Although the weight of animals
remained steady during rest of the study in nontumor and
Td-pcDNA3-1 implanted animals, Td-IL-1-implanted an-
imals displayed progressive loss of weight. Thus, loss of
body weight is an active cachetic process but not simply
because of IL-1-induced arrest of growth. Note that all
animals were of the same age group and weight at the
time of tumor cell implantation. We performed H&E stain-
ing of dorsal skin to further analyze cachexia. Skin of
Td-IL-1 tumor-bearing mice showed diffused atrophy of
both epidermis and adnexal structures (hair follicle buds
and sweat glands) compared to animals with Td-pcDNA3
tumor-bearing animals (Figure 4B). Similar skin abnor-
malities have been observed in ob/ob mice injected with
leptin and in mice lacking acyl coA:diacylglycerol acyl-
transferase, which is essential for triglyceride synthe-
sis.42 Skin abnormalities are frequently observed during
premature aging and cachexia.41 Skin abnormalities de-
tected with Td-IL-1 tumor-bearing mice closely resem-
bled the prematurely aged skin of mice overexpressing
dominantly acting p53 but not that of mice with defects in
DNA repair.41,43
Animals with Td-IL-13-Derived Tumors
Contain Elevated Serum Leptin
To investigate whether IL-1-induced cachexia corre-
lates with any changes in metabolic pathways, we mea-
sured glucose, triglycerides, calcium, and leptin levels in
blood/serum. Blood glucose was measured twice (after 6
weeks of implantation and at the time of sacrifice)
whereas calcium, triglycerides and leptin were measured
once at the time of sacrifice. There was no significant
difference in blood glucose between Td-IL-13 and Td-
pcDNA3-1 groups (Table 1). In contrast, the Td-IL-13
group showed lower levels of triglycerides compared to
the Td-pcDNA3-1 group. The differences were highly
significant (P  0.0007). Altered triglyceride levels have
been reported in cachexia patients.44,45 Higher levels of
serum calcium were detected in the Td-IL-13 group
compared to animals in the Td-pcDNA3-1 group (Table
1). Most importantly, leptin levels were higher in serum of
animals in the Td-IL-13 group compared to animals in
the Td-pcDNA3-1 group (Table 1). Higher leptin levels
have been detected in serum of breast cancer patients
and in breast cancer specimens and elevated leptin lev-
els correlated with cachexia parameters.46,47
Leptin has been shown to control food intake by acting
through the central nervous system.48 It is possible that
cachexia in Td-IL-1 tumor-bearing animals is an indirect
consequence of leptin-mediated decrease in food intake.
To test this possibility, we measured food intake twice
weekly between weeks 4 and 7 after implantation. To our
surprise, food consumption was modestly higher in Td-
IL-13 group compared to Td-pcDNA3-1 group (Table
1). Therefore, loss of body weight in Td-IL-13 tumor-
bearing animals is not because of anorexia.
Tumors from the Td-IL-13 Group Contain
Higher Levels of Leptin but Not LMF Transcripts
Leptin is generally secreted by adipocytes. However,
examination of the skin (Figure 4B) or abdomen did not
reveal any increase in adipocytes in animals with Td-IL-
13 compared to animals with Td-pcDNA3-1-derived tu-
mors. Therefore, the tumor itself is the likely source of
leptin. To test this possibility, we performed RT-PCR anal-
ysis of RNA from tumor tissue for human and mouse
leptin. PCR-amplified products were not detected with
primers that specifically amplify human leptin. In contrast,
mouse leptin transcripts could be detected in RNA from
Td-IL-13 groups but not Td-pcDNA3-1 groups (Figure
4C). Similar results were obtained when PCR was per-
formed with a different set of primers (data not shown).
H&E staining of tumor samples failed to detect any adi-
pocytes in tumors of both Td-IL-13 or Td-pcDNA3-1
groups (data not shown). These results suggest that
IL-1 produced by tumor cells recruits nonadipocyte
cells that can produce leptin.
Previous studies have shown that altered lipid metab-
olism in cancer patients is mediated by LMF.49 LMF,
Figure 4. The effect of IL-1 expression in cancer cells on body weight and mouse leptin transcripts. A: Weight of animals implanted with Td-pcDNA3-1 (square)
or Td-IL-13 (triangle) (n  30). Weight of animals without any tumor is also shown (circle). P  0.0001 nontumor versus Td-IL-13; P  0.0003
Td-pcDNA3-1 versus Td-IL-13; P 0.0839 nontumor versus Td-pcDNA3-1. B: Skin phenotype of Td-pcDNA3 and Td-IL-1 tumor-bearing animals. Cross sections
of dorsal skin show atrophy in Td-IL-1 tumor-bearing animals compared to Td-pcDNA3 tumor-bearing animals. SM, skeletal muscle; HF, hair follicle; SG
sebaceous glands; ED, epidermis. C: Human LMF and mouse leptin-specific transcript levels in tumor samples. Total RNA from tumors was subjected to RT-PCR
(35 cycles) using primers that specifically amplify mouse leptin RNA. Primers corresponding to human LMF were used to amplify LMF (35 cycles). Quality of RNA
as well as cDNA synthesis was verified by PCR amplification of the housekeeping gene GAPDH (18 cycles). Southern blotting of PCR products with an internal
primer as a probe and autoradiography identified PCR products. Because of limited amplification, PCR products were not visible by ethidium bromide staining.
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which is identical to Zn-2-glycoprotein, is expressed in
breast cancer cells.50 To determine whether IL-1 di-
rectly modulates LMF expression, we measured human
LMF expression by RT-PCR. LMF does not appear to be
the direct target of IL-1 (Figure 4C). In fact, LMF tran-
scripts appear to be higher in the Td-pcDNA3-1 group
compared to the Td-IL-13 group.
Loss of Body Weight in Animals with Td-IL-13-
Derived Tumors Is Not Associated with
Increased Levels of Other Known Inducers of
Cachexia
NF-B has been proposed to promote cachexia by down-
regulating MyoD mRNA.51 Because IL-1 can potentially
reduce MyoD through activation of NF-B, we measured
the level of MyoD proteins in muscle by Western blotting
(Figure 5A). Densitometric scanning analysis showed
that MyoD protein levels tended to be lower in muscles of
animals with Td-IL-13-derived tumors compared to Td-
pcDNA3-1-derived tumors (P  0.0542). Recent reports
indicate that ubiquitination of proteins in muscle is in-
creased during cachexia, particularly when cachexia is
mediated by proteolysis-inducing factor (PIF).52,53 How-
ever, the level of ubiquitinated proteins was similar in
both Td-IL-13 and Td-pcDNA3-1 groups (Figure 5A).
Also, the muscle from both groups lacked myostatin/
GDF8, which has recently been proposed to be a major
cachexia-inducing protein expressed in muscle (data not
shown).54 We measured 20S proteasome activity in the
muscle of Td-pcDNA3-1 and Td-IL-13 tumor-bearing
animals to further clarify the role of PIF in cachexia.
Proteasomal activity was similar in both groups, which
rules out the involvement of PIF in IL-1-induced ca-
chexia (Table 1).
Several cytokines including TNF- and IL-6 induce
cachexia and both TNF- and IL-6 can be induced by
IL-1 through activation of NF-B.55,56 To test whether
any of these circulating cytokines are elevated in animals
with Td-IL-13-derived tumors compared to animals with
Td-pcDNA3-1-derived tumors, serum was subjected to
LINCOplex cytokine multiplex immunoassay. The assay
simultaneously measures the level of IL-1, IL-2, IL-4,
IL-5, IL-6, IL-10, IL-12, interferon (IFN)-, GM-CSF, and
TNF- with a sensitivity of 3.2 pg/ml of serum. Only those
cytokines that are present in most of the animals are
shown in Figure 5B. There were no significant differences
in any of the cytokines tested although the IL-6 level
appears to be slightly elevated in the Td-IL-13 group.
Note that the difference in IL-6 is statistically significant if
one animal in the Td-pcDNA3-1 group, which showed
unusually high level of IL-6, is excluded from the calcu-
lation. Taken together, it appears that IL-1-induced
weight loss is less likely because of up-regulation of
TNF- and IL-6 by IL-1.
Table 1. Blood Glucose, Triglycerides, Serum Calcium, Leptin Level, Food Intake, and 20S Proteasome Activity
Td-IL-1 group Td-pcDNA3 group p Values
Blood glucose (mg/dl) 75.4  4.4 78.63  4.3 0.6233
Triglycerides (mg/dl) 55.5  5.3 85.9  5.2 0.0006
Serum calcium (mg/dl) 10.4  1.5 9.2  1.4 0.0423
Leptin (ng/ml) 1.95  0.18 1.03  0.32 0.0133
20S Proteasome activity 19.5  0.8 23.1  1.2 0.0512
Food intake (g/mouse/day) 6.3  0.3 4.7  0.3 0.0032
Blood glucose was measured twice during the course of the experiment and average with standard error from both experiments is presented.
Triglycerides, calcium, and leptin were measured in serum collected at the time of sacrifice. Proteasome activity is expressed as arbitrary units.
Figure 5. The effect of IL-1 expression in cancer cells on muscle protein
status and serum cytokine profile. A: Differences in the level of MyoD,
ubiquitinated protein, and -tubulin in leg muscle. Muscle extracts were
prepared using RIPA buffer and 50 g of protein was subjected to Western
blotting with indicated antibodies. B: Profile of various cytokines in serum of
animals implanted with different cell types.
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Discussion
IL-1s are present in abundance in the tumor microenvi-
ronment and are believed to play a role in growth, inva-
siveness, and anti-tumor immunity.57 Anti-tumor activity
of IL-1 has been demonstrated for lymphoid tumors and
fibrosarcoma using an animal model.18,58 Membrane-
associated form of IL-1 but not the secreted form is
believed to initiate anti-tumor immunity.18 Because IL-1
is overexpressed in ductal carcinoma in situ and in inva-
sive but not in benign mammary tumors, it is likely that
breast cancer cells have somehow overcome the anti-
tumor activity of IL-1, as with many cancers.11,59 Fur-
thermore, IL-1 expression is observed mostly in estro-
gen receptor -negative breast cancer, which are usually
more invasive and metastatic and is associated with poor
prognosis.60 It is suggested that IL-1 is important in
regulating protumorigenic activities within the tumor mi-
croenvironment.60 To understand the effect of IL-1 over-
expression on cancer progression in vivo, we used the
nude mice model. Despite limitations of this model, we
observed two major effects of IL-1, one on the growth of
tumor and the other on the metabolic status. When this
manuscript was under revision, Voronov and col-
leagues61 reported a similar finding using IL-1 knockout
animals. IL-1 is required for tumor invasiveness and
angiogenesis. Growth stimulation by IL-1 appears to
depend on tumor cell-stromal cell interaction because
parental and IL-1-overexpressing cells grew at a similar
rate in vitro (data not shown). The growth-promoting fac-
tors induced as a consequence of tumor cell-stromal cell
interaction remain to be identified. One possible candi-
date is leptin, whose expression is increased in animals
with IL-1-producing tumors. Leptin has been shown to
increase the proliferation of MCF-7 cells in vitro.62 Leptin
also increases endothelial cell proliferation, which can
lead to increased angiogenesis and tumor cell prolifera-
tion.48,63
A major observation of our study is cachexia in animals
injected with IL-1-overexpressing cancer cells. Ca-
chexia was accompanied with changes in the skin archi-
tecture, which resembled that of premature aging. Ca-
chexia is generally a consequence of loss of lipids,
enhanced proteolysis or both, although lipid depletion
occurs out of proportion to the protein loss.64,65 IL-6, IL-8,
TNF-, IFN-, leukemia inhibitory factor, myostatin/GDF8,
PIF, LMF, and toxohormone are some of the factors in-
volved in cachexia.54,55,66,67 IFN- in combination with
TNF- has been shown to induce cachexia through NF-
B-dependent destabilization of MyoD mRNA in mus-
cle.51 We were unable to measure all of these factors in
serum because of limited sample availability or lack of
commercially available antibodies. However, among the
factors measured, we did not see any significant differ-
ences between Td-IL-13 and Td-pcDNA3-1 groups.
Moreover, differences in MyoD were marginal with no
difference in ubiquitinated proteins and proteasome ac-
tivity in muscle between groups, which rules out the
involvement of IFN-, TNF-, and PIF in cachexia in our
model.53,68
Cachexia in the Td-IL-13 group correlated with ele-
vated leptin level. Elevated leptin is observed in breast
cancer patients with cachexia and increased leptin-like
signaling by cytokines is the hallmark of cachexia.46,69
Similarly, elevated leptin is linked to cachexia in patients
with chronic heart failure.70 Leptin is secreted mainly by
adipocytes. However leptin expression in nonadipocytes,
including breast cancer cell lines, has been observed
and its expression is IL-1-inducible.47,71–73 Histological
analysis of tumors did not indicate any effect of IL-1 on
adipocyte content in the tumor (data not shown). RT-PCR
analysis of tumor RNA with human leptin-specific primers
failed to detect human leptin (data not shown). In con-
trast, mouse-specific leptin transcripts could be de-
tected in total RNA of tumors derived from Td-IL-13
cells (Figure 4). Thus, IL-1 increases leptin expres-
sion in mouse-derived stromal cells or in infiltrating
immune cells. Interestingly, Td-IL-13 tumor-bearing
animals were not anorexic despite elevated leptin lev-
els. Thus, cachexia is not a consequence of reduced
food intake, which is consistent with some of the clin-
ical observations.65 It is recognized recently that leptin
acts both at the central nervous system and at the
peripheral level.48 While action at the central nervous
system controls food intake, action at the periphery
controls insulin action, glucose transport, lipogenesis,
and lipid partitioning. For example, leptin directly inhibits
de novo synthesis of fatty acids and increases the release
and oxidation of fatty acids in adipocytes.48,74 Moreover,
leptin reduces incorporation of oleate into triglycerides,48
which can explain for reduced triglycerides and body
weight in Td-IL-13 tumor-bearing animals. It is interest-
ing that LIF, which induces cachexia by mobilizing lipids,
causes a modest decrease in triglyceride levels in leptin-
sensitive wild-type mice but not in leptin-deficient ob/ob
mice.49 Based on the recent realization that leptin biology
is much more complex than originally envisioned,48 we
propose that leptin is a central player in cachexia involv-
ing impaired lipid metabolism. At present, we cannot
conclude that leptin alone is responsible for enhanced
tumor growth and cachexia in mice implanted with Td-IL-
13 cells. Additional studies with neutralizing antibodies
against leptin are essential, which we believe is beyond
the scope of this investigation. This study at least pro-
vides a basis for future investigation in this direction.
One of the surprising observations is the failure of
IL-1-overexpressing tumor cells to metastasize, al-
though in vitro studies supported such a possibility. Fail-
ure of IL-1 to initiate metastasis could be because of
expression of a dominant metastasis suppressor gene in
MCF-7 cells or alternatively, genes that initiate metastasis
are not expressed in these cells or are not induced by
IL-1. In this regard, it was shown recently that loss of
metastasis suppressor gene expression is essential for
metastatic progression of prostate cancer.75 Also, it was
reported that the promoter of uPA is methylated in MCF-7
cells, thus making it inaccessible to IL-1-induced NF-
B.35 uPA is one of the major proteases involved in
initiation of metastasis.76 It will be interesting to determine
whether enforced expression of uPA in Td-IL-13 cells
can initiate metastasis in vivo.
Role of IL-1 in Breast Cancer 2539
AJP December 2003, Vol. 163, No. 6
Acknowledgments
We thank P. Bhat-Nakshatri, C. Stauss, and J. Dunn for
technical assistance; Y. C. Yang for IL-1 cDNA; Suzan
C. Hufferd, Gregory Reid Gibson, Ronald McClintock,
and Mark Deeg for serum cytokine, calcium, and leptin
measurements; and Andrea Carperell-Grant and Robert
Harris for advice.
References
1. Liotta LA, Stetler-Stevenson WG, Steeg PS: Cancer invasion and
metastasis: positive and negative regulatory elements. Cancer Invest
1991, 9:543–551
2. Liotta LA: An attractive force in metastasis. Nature 2001, 410:24–25
3. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClana-
han T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Veras-
tegui E, Zlotnik A: Involvement of chemokine receptors in breast
cancer metastasis. Nature 2001, 410:50–56
4. Lewis CE, Leek R, Harris A, McGee JO: Cytokine regulation of angio-
genesis in breast cancer: the role of tumor-associated macrophages.
J Leukoc Biol 1995, 57:747–751
5. van Eys J: Nutrition and cancer: physiological interrelationships. Annu
Rev Nutr 1985, 5:435–461
6. Leek RD, Harris AL, Lewis CE: Cytokine networks in solid human
tumors: regulation of angiogenesis. J Leukoc Biol 1994, 56:423–435
7. Tisdale MJ: Wasting in cancer. J Nutr 1999, 129:243S–246S
8. Baracos VE: Regulation of skeletal-muscle-protein turnover in cancer-
associated cachexia. Nutrition 2000, 16:1015–1018
9. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh
NT, Mukaida N, Van Waes C: IL (interleukin)-1alpha promotes nuclear
factor-kappaB and AP-1-induced IL-8 expression, cell survival, and
proliferation in head and neck squamous cell carcinomas. Clin Can-
cer Res 2001, 7:1812–1820
10. Bhat-Nakshatri P, Newton TR, Goulet Jr R, Nakshatri H: NF-kappaB
activation and interleukin 6 production in fibroblasts by estrogen
receptor-negative breast cancer cell-derived interleukin 1alpha. Proc
Natl Acad Sci USA 1998, 95:6971–6976
11. Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M,
Lindquist RR, Barrows G, Kreutzer DL: Cytokines in human breast
cancer: IL-1alpha and IL-1beta expression. Oncol Rep 1999, 6:65–70
12. Newton TR, Patel NM, Bhat-Nakshatri P, Stauss CR, Goulet Jr RJ,
Nakshatri H: Negative regulation of transactivation function but not
DNA binding of NF-kappaB and AP-1 by IkappaBbeta1 in breast
cancer cells. J Biol Chem 1999, 274:18827–18835
13. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S,
Gelfanov V, Boswell SH, Goulet Jr RJ, Sledge Jr GW, Nakshatri H:
Paclitaxel sensitivity of breast cancer cells with constitutively active
NF-kappaB is enhanced by IkappaBalpha super-repressor and par-
thenolide. Oncogene 2000, 19:4159–4169
14. Nozaki S, Sledge Jr GW, Nakshatri H: Cancer cell-derived interleukin
1alpha contributes to autocrine and paracrine induction of pro-met-
astatic genes in breast cancer. Biochem Biophys Res Commun 2000,
275:60–62
15. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 1996,
87:2095–2147
16. Carruth LM, Demczuk S, Mizel SB: Involvement of a calpain-like
protease in the processing of the murine interleukin 1 alpha precur-
sor. J Biol Chem 1991, 266:12162–12167
17. Stevenson FT, Turck J, Locksley RM, Lovett DH: The N-terminal
propiece of interleukin 1 alpha is a transforming nuclear oncoprotein.
Proc Natl Acad Sci USA 1997, 94:508–513
18. Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M,
White RM, Zoller M, Barak V, Segal S, Apte RN: Antitumor and
immunotherapeutic effects of activated invasive T lymphoma cells
that display short-term interleukin 1alpha expression. Cancer Res
1999, 59:1029–1035
19. Watanabe N, Kobayashi Y: Selective release of a processed form of
interleukin 1 alpha. Cytokine 1994, 6:597–601
20. Chen Z, Colon I, Ortiz N, Callister M, Dong G, Pegram MY, Arosarena
O, Strome S, Nicholson JC, Van Waes C: Effects of interleukin-1alpha,
interleukin-1 receptor antagonist, and neutralizing antibody on proin-
flammatory cytokine expression by human squamous cell carcinoma
lines. Cancer Res 1998, 58:3668–3676
21. Kock A, Schwarz T, Urbanski A, Peng Z, Vetterlein M, Micksche M,
Ansel JC, Kung HF, Luger TA: Expression and release of interleukin-1
by different human melanoma cell lines. J Natl Cancer Inst 1989,
81:36–42
22. Zhang L, Kharbanda S, McLeskey SW, Kern FG: Overexpression of
fibroblast growth factor 1 in MCF-7 breast cancer cells facilitates
tumor cell dissemination but does not support the development of
macrometastases in the lungs or lymph nodes. Cancer Res 1999,
59:5023–5029
23. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis
S, Henney CS, Kronheim SR, Grabstein K, Conlon PJ, Hopp TP,
Cosman D: Cloning, sequence and expression of two distinct human
interleukin-1 complementary DNAs. Nature 1985, 315:641–647
24. Sledge Jr GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix
metalloproteinase inhibitor batimastat on breast cancer regrowth and
metastasis in athymic mice. J Natl Cancer Inst 1995, 87:1546–1550
25. Ovejera AA, Houchens DP, Barker AD: Chemotherapy of human
tumor xenografts in genetically athymic mice. Ann Clin Lab Sci 1978,
8:50–56
26. Kishimoto H, Urade M, Sakurai K, Noguchi K: Isolation and charac-
terisation of adenoid squamous carcinoma cells highly producing
SCC antigen and CEA from carcinoma of the maxillary sinus. Oral
Oncol 2000, 36:70–75
27. Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK: Anabolic
actions of parathyroid hormone during bone growth are dependent
on c-fos. Endocrinology 2002, 143:4038–4047
28. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr
GW: Constitutive activation of NF-kappaB during progression of
breast cancer to hormone-independent growth. Mol Cell Biol 1997,
17:3629–3639
29. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H: Identification of signal
transduction pathways involved in constitutive NF-kappaB activation
in breast cancer cells. Oncogene 2002, 21:2066–2078
30. Fife RS, Sledge Jr GW: Effects of doxycycline on in vitro growth,
migration, and gelatinase activity of breast carcinoma cells. J Lab
Clin Med 1995, 125:407–411
31. Li B, Dou QP: Bax degradation by the ubiquitin/proteasome-depen-
dent pathway: involvement in tumor survival and progression. Proc
Natl Acad Sci USA 2000, 97:3850–3855
32. Endo Y, Sasaki T, Harada F, Noguchi M: Specific detection of me-
tastasized human tumor cells in embryonic chicks by the polymerase
chain reaction. Jpn J Cancer Res 1990, 81:723–726
33. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolu-
tionarily conserved mediators of immune responses. Annu Rev Im-
munol 1998, 16:225–260
34. Helbig G, Christopherson II KW, Bhat-Nakshatri P, Kumar S, Kishi-
moto H, Miller KD, Broxmeyer HE, Nakshatri H: NF-kappaB promotes
breast cancer cell migration and metastasis by inducing the expres-
sion of the chemokine receptor CXCR4. J Biol Chem 2003, 278:
21631–21638
35. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA: Regu-
lation of DNA methylation in human breast cancer. Effect on the
urokinase-type plasminogen activator gene production and tumor
invasion. J Biol Chem 2002, 277:41571–41579
36. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR: MCF10AT: a
model for the evolution of cancer from proliferative breast disease.
Am J Pathol 1996, 148:313–319
37. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA,
Nicholas RW, Suva LJ: Expression of interleukin 8 and not parathyroid
hormone-related protein by human breast cancer cells correlates with
bone metastasis in vivo. Cancer Res 2002, 62:5571–5579
38. Wiseman BS, Werb Z: Stromal effects on mammary gland develop-
ment and breast cancer. Science 2002, 296:1046–1049
39. Lee PP, Hwang JJ, Mead L, Ip MM: Functional role of matrix metal-
loproteinases (MMPs) in mammary epithelial cell development. J Cell
Physiol 2001, 188:75–88
40. Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, Hirtenle-
hner K, Seifert M, Kubista E: MMP-2 and MMP-9 expression in breast
cancer-derived human fibroblasts is differentially regulated by stro-
mal-epithelial interactions. Breast Cancer Res Treat 2002, 72:69–77
41. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N,
2540 Kumar et al
AJP December 2003, Vol. 163, No. 6
Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Hee Park S,
Thompson T, Karsenty G, Bradley A, Donehower LA: p53 mutant
mice that display early ageing-associated phenotypes. Nature 2002,
415:45–53
42. Chen HC, Smith SJ, Tow B, Elias PM, Farese Jr RV: Leptin modulates
the effects of acyl CoA:diacylglycerol acyltransferase deficiency on
murine fur and sebaceous glands. J Clin Invest 2002, 109:175–181
43. de Boer J, Andressoo JO, de Wit J, Huijmans J, Beems RB, van Steeg
H, Weeda G, van der Horst GT, van Leeuwen W, Themmen AP,
Meradji M, Hoeijmakers JH: Premature aging in mice deficient in DNA
repair and transcription. Science 2002, 296:1276–1279
44. Briddon S, Beck SA, Tisdale MJ: Changes in activity of lipoprotein
lipase, plasma free fatty acids and triglycerides with weight loss in a
cachexia model. Cancer Lett 1991, 57:49–53
45. Gercel-Taylor C, Doering DL, Kraemer FB, Taylor DD: Aberrations in
normal systemic lipid metabolism in ovarian cancer patients. Gynecol
Oncol 1996, 60:35–41
46. Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM,
Benedetto C, Mussa A: Leptin expression in colorectal and breast
cancer patients. Int J Mol Med 2000, 5:421–426
47. O’Brien SN, Welter BH, Price TM: Presence of leptin in breast cell
lines and breast tumors. Biochem Biophys Res Commun 1999, 259:
695–698
48. Margetic S, Gazzola C, Pegg GG, Hill RA: Leptin: a review of its
peripheral actions and interactions. Int J Obes Relat Metab Disord
2002, 26:1407–1433
49. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ: Biological
evaluation of a lipid-mobilizing factor isolated from the urine of cancer
patients. Cancer Res 1998, 58:2359–2365
50. Freije JP, Fueyo A, Uria J, Lopez-Otin C: Human Zn-alpha 2-glyco-
protein cDNA cloning and expression analysis in benign and malig-
nant breast tissues. FEBS Lett 1991, 290:247–249
51. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin Jr AS:
NF-kappaB-induced loss of MyoD messenger RNA: possible role in
muscle decay and cachexia. Science 2000, 289:2363–2366
52. Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B,
Huang JQ, Pierce JW, Read MA, Coggins MB, Solomon V, Goldberg
AL, Brand SJ, Elliott PJ: A new model of cancer cachexia: contribution
of the ubiquitin-proteasome pathway. Am J Physiol 1999, 277:E332–
E341
53. Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ: Mecha-
nism of muscle protein degradation induced by a cancer cachectic
factor. Br J Cancer 1998, 78:850–856
54. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkin-
son KN, McPherron AC, Wolfman NM, Lee SJ: Induction of cachexia
in mice by systemically administered myostatin. Science 2002, 296:
1486–1488
55. Argiles JM, Lopez-Soriano FJ: The role of cytokines in cancer ca-
chexia. Med Res Rev 1999, 19:223–248
56. Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the
immune system. Annu Rev Immunol 1994, 12:141–179
57. Apte RN, Voronov E: Interleukin-1-a major pleiotropic cytokine in
tumor-host interactions. Semin Cancer Biol 2002, 12:277–290
58. Douvdevani A, Huleihel M, Zoller M, Segal S, Apte RN: Reduced
tumorigenicity of fibrosarcomas which constitutively generate IL-1
alpha either spontaneously or following IL-1 alpha gene transfer. Int J
Cancer 1992, 51:822–830
59. Carbone JE, Ohm DP: Immune dysfunction in cancer patients. On-
cology (Huntingt) 2002, 16:11–18
60. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M,
Lindquist R, Barrows G, Kreutzer DL: Interleukin-1 family expression
in human breast cancer: interleukin-1 receptor antagonist. Cancer
Invest 2000, 18:293–302
61. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura
Y, Dinarello CA, Apte RN: IL-1 is required for tumor invasiveness and
angiogenesis. Proc Natl Acad Sci USA 2003, 100:2645–2650
62. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC,
Pecquery R, Giudicelli Y: Leptin mediates a proliferative response in
human MCF7 breast cancer cells. Biochem Biophys Res Commun
2002, 293:622–628
63. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho
SY, Kim HS: Potential role of leptin in angiogenesis: leptin induces
endothelial cell proliferation and expression of matrix metalloprotein-
ases in vivo and in vitro. Exp Mol Med 2001, 33:95–102
64. McAndrew PF: Fat metabolism and cancer. Surg Clin North Am 1986,
66:1003–1012
65. Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer 2002,
2:862–871
66. Tisdale MJ: Metabolic abnormalities in cachexia and anorexia. Nutri-
tion 2000, 16:1013–1014
67. Rubin H: Cancer cachexia: its correlations and causes. Proc Natl
Acad Sci USA 2003, 100:5384–5389
68. Smith HJ, Tisdale MJ: Induction of apoptosis by a cachectic-factor in
murine myotubes and inhibition by eicosapentaenoic acid. Apoptosis
2003, 8:161–169
69. Inui A, Meguid MM: Cachexia and obesity: two sides of one coin?
Curr Opin Clin Nutr Metab Care 2003, 6:395–399
70. Schulze PC, Kratzsch J, Linke A, Schoene N, Adams V, Gielen S,
Erbs S, Moebius-Winkler S, Schuler G: Elevated serum levels of leptin
and soluble leptin receptor in patients with advanced chronic heart
failure. Eur J Heart Fail 2003, 5:33–40
71. Wilding JP: Leptin and the control of obesity. Curr Opin Pharmacol
2001, 1:656–661
72. Iguchi M, Aiba S, Yoshino Y, Tagami H: Human follicular papilla cells
carry out nonadipose tissue production of leptin. J Invest Dermatol
2001, 117:1349–1356
73. Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR, Grunfeld
C: IL-1 beta mediates leptin induction during inflammation. Am J
Physiol 1998, 274:R204–R208
74. William Jr WN, Ceddia RB, Curi R: Leptin controls the fate of fatty
acids in isolated rat white adipocytes. J Endocrinol 2002, 175:735–
744
75. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha
C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA,
Chinnaiyan AM: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature 2002, 419:624–629
76. Edwards DR, Murphy G: Cancer. Proteases—invasion and more.
Nature 1998, 394:527–528
77. Gabig TG, Crean CD, Klenk A, Long H, Copeland NG, Gilbert DJ,
Jenkins NA, Quincey D, Parente F, Lespinasse F, Carle GF, Gaudray
P, Zhang CX, Calender A, Hoeppener J, Kas K, Thakker RV, Farnebo
F, Teh BT, Larsson C, Piehl F, Lagercrantz J, Khodaei S, Carson E,
Weber G: Expression and chromosomal localization of the Requiem
gene. Mamm Genome 1998, 9:660–665
Role of IL-1 in Breast Cancer 2541
AJP December 2003, Vol. 163, No. 6
